Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2006 Feb;44(2):595-7.
doi: 10.1128/JCM.44.2.595-597.2006.

Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis

Francisco M Marty  1 , Wendy W Yeh, Christine B Wennersten, Lata Venkataraman, Esperanza Albano, Edwin P Alyea, Howard S Gold, Lindsey R Baden, Satish K Pillai
Affiliations
Case Reports

Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis

Francisco M Marty et al. J Clin Microbiol. 2006 Feb.

Abstract

The emergence of a clinically daptomycin-resistant Staphylococcus aureus isolate occurred during treatment of methicillin-resistant S. aureus bacteremia and probable vertebral osteomyelitis. The breakthrough isolate was indistinguishable from pretreatment daptomycin-susceptible isolates by pulsed-field gel electrophoresis. Daptomycin nonsusceptibility was confirmed by MIC and time-kill curve analyses.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Pulsed-field gel electrophoresis. The lanes contain the following from left to right, respectively: marker strain NCTC 8325 (17), S. aureus A8796, S. aureus A8797, S. aureus A8798, and S. aureus A8799.
FIG. 2.
FIG. 2.
Time-kill curves for S. aureus A8796, A8797, A8798, and A8799 in the presence of 8 μg/ml daptomycin. The data at each time point represent the averages of two experiments.
See this image and copyright information in PMC

References

    1. Arbeit, R. D., D. Maki, F. P. Tally, E. Campanaro, and B. I. Eisenstein. 2004. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin. Infect. Dis. 38:1673-1681. - PubMed
    1. Carpenter, C. F., and H. F. Chambers. 2004. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens. Clin. Infect. Dis. 38:994-1000. - PubMed
    1. Center for Drug Evaluation and Research, Food and Drug Administration. 15. December 2003, posting date. NDA 21-572, CubicinTM (daptomycin for injection). [Online.] http://www.fda.gov/cder/foi/nda/2003/21-572_Cubicin_Microbr_P2.pdf. Accessed 12 June 2005.
    1. Clinical and Laboratory Standards Institute. 2005. Performance standards for antimicrobial susceptibility testing; fifteenth informational supplement, M100-S15. Clinical and Laboratory Standards Institute, Wayne, Pa.
    1. Cubist Pharmaceuticals, Inc. 2003, posting date. CubicinTM (daptomycin for Injection), prescriber information. [Online.] http://www.cubicin.com/documents/cubicin_large_pi.pdf. Accessed 12 June 2005.

Publication types

MeSH terms

LinkOut - more resources